Chief, Myeloma Service, Memorial Sloan Kettering Cancer Centre, New York, USA
I am a board-certified hematologist-oncologist whose research focuses on the development of novel treatment strategies and advanced disease monitoring by new minimal residual disease (MRD) assays, as well as biological studies focusing on disease and host biology. I also study mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. I have a strong interest in the development of early-treatment clinical trials targeting high-risk smoldering myeloma.
I am one of the pioneers in the development of MRD testing in myeloma. In collaboration with colleagues at MSK as well nationally/internationally, I develop new strategies (including cell-based, molecular-based, and imaging-based) and implement advanced MRD testing in clinical trials at MSK.
I am involved in the service’s rational treatment program (small molecule, monoclonal antibody, immune-based) for newly diagnosed, relapsed and refractory myeloma and amyloidosis patients.
In addition, I lead the development of a structured program for the education and mentoring of residents and fellows in the Myeloma Service. The service also takes part in regular multi-disciplinary clinical conferences and scientific meetings.
I am also fluent in English, Swedish and German.